Annual progress of transcatheter mitral valve intervention in 2022_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

BAI Lin , CHEN Fei , ZHAO Zhengang , PENG Yong , FENG Yuan ,  CHEN Mao

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;

Corresponding author：

CHEN Mao, Email: hmaochen@vip.sina.com

Keywords：

Mitral regurgitation; transcatheter mitral valve intervention; transcatheter mitral valve repair; transcatheter edge-to-edge repair; transcatheter mitral valve replacement

DOI：

10.7507/1007-4848.202302059

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Mitral regurgitation is the most common heart valvular disease at present. In the past, mitral regurgitation was mainly treated by surgical mitral valve repair or replacement. However, with the progress of transcatheter interventional techniques and instruments in recent years, transcatheter mitral valve interventional therapy has gradually shown its advantages and benefited patients. The purpose of this article is to review the progress of transcatheter mitral valve intervention in this year, and to provide prospects for the future of transcatheter mitral valve treatment.

Citation： BAI Lin, CHEN Fei, ZHAO Zhengang, PENG Yong, FENG Yuan, CHEN Mao. Annual progress of transcatheter mitral valve intervention in 2022. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(6): 805-811. doi: 10.7507/1007-4848.202302059 Copy

1.	Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: A population-based study. Lancet, 2006, 368(9540): 1005-1011.
2.	Goel K. COAPT PAS: 1 year outcomes from 5000 patients. ESC 2022, 28 August 2022, Barcelona, Spain.
3.	Tang G. One-year outcomes in patients with secondary MR outside the COAPT criteria: From the MitraClip™ global EXPAND study. TVT 2022, 8 June 2022, Chicago, USA.
4.	Jasona R. Contemporary clinical and echocardiographic outcomes of 1000+ patients treated with mitraClip™ G4: Results from the EXPAND G4 Post Approval Study. TCT 2022, 18 September 2022, Boston, USA.
5.	Munafò AR. Two-year outcomes of MitraClip as a bridge to heart transplantation: The MitraBridge Registry. EuroPCR 2022, 17 May 2022, Paris, France.
6.	Song C, Madhavan MV, Lindenfeld J, et al. Age-related outcomes after transcatheter mitral valve repair in patients with heart failure: Analysis from COAPT. JACC Cardiovasc Interv, 2022, 15(4): 397-407.
7.	Beohar N, Ailawadi G, Kotinkaduwa LN, et al. Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: The COAPT trial. Eur Heart J, 2022, 43(17): 1639-1648.
8.	Simard T, Vemulapalli S, Jung RG, et al. Transcatheter edge-to-edge mitral valve repair in patients with severe mitral regurgitation and cardiogenic shock. J Am Coll Cardiol, 2022, 80(22): 2072-2084.
9.	Rubbio A. MitraClip in atrial functional mitral regurgitation: A multi-center experience The MITRA-TUNE Registry. EuroPCR 2022, 17 May 2022, Paris, France.
10.	Doldi P, Stolz L, Orban M, et al. Transcatheter mitral valve repair in patients with atrial functional mitral regurgitation. JACC Cardiovasc Imaging, 2022, 15(11): 1843-1851.
11.	Sodhi N, Asch FM, Ruf T, et al. Clinical outcomes with transcatheter edge-to-edge repair in atrial functional MR from the EXPAND study. JACC Cardiovasc Interv, 2022, 15(17): 1723-1730.
12.	Tanaka T, Sugiura A, Öztürk C, et al. Transcatheter edge-to-edge repair for atrial secondary mitral regurgitation. JACC Cardiovasc Interv, 2022, 15(17): 1731-1740.
13.	Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv, 2022, 15(24): 2523-2536.
14.	Hausleiter J. The PASCAL ⅡD Registry: A prospective registry for transcatheter edge-to-edge repair in prohibitive risk patients with degenerative mitral regurgitation and complex mMitral valve anatomy. TCT 2022. September18, 2022, Boston, USA.
15.	Lurz P. One-year outcomes for transcatheter mitral repair from the MiCLASP study. PCR London Valves 2022, 28 November 2022, London, United Kingdom.
16.	Spargias K. Three-year outcomes for transcatheter mitral repair from the CLASP study. PCR London Valves 2022, 28 November 2022, London, United Kingdom.
17.	Raposeiras-Roubin S, Adamo M, Freixa X, et al. A score to assess mortality after percutaneous mitral valve repair. J Am Coll Cardiol, 2022, 79(6): 562-573.
18.	Latib A, Ho EC, Scotti A, et al. First-in-human transseptal transcatheter mitral chordal repair. JACC Cardiovasc Interv, 2022, 15(17): 1768-1769.
19.	Scotti A, Galasso M, Margonato A, et al. Patient selection for trans-catheter mitral valve repair vs. replacement: Ongoing indications and glimpse to the future. Vessel Plus, 2021, 5: 6.
20.	Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses. J Am Coll Cardiol, 2022, 80(23): 2171-2183.
21.	Ben Ali W, Ludwig S, Duncan A, et al. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI Registry. Eur J Heart Fail, 2022, 24(5): 887-898.
22.	Zahr F. Transfemoral TMVR: Intermediate-term outcomes from the Intrepid Early Feasibility Study. TCT 2022. September18, 2022, Boston, USA.
23.	Jain REA. Midterm echocardiographic outcomes following transapical mitral valve replacement: Updates from the Intrepid Pilot Study. TCT 2022, September19, 2022, Boston, USA.
24.	Rottbauer W. HighLife TSMVR and their latest experiences, moving forward. PCR London Valves 2022, 29 November 2022, London, United Kingdom.
25.	Wild MG, Kreidel F, Hell MM, et al. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: A real-world multicentre experience. Eur J Heart Fail, 2022, 24(5): 899-907.
26.	Duncan A. One-year outcomes of tendyne TMVR treating symptomatic MR: Expanded study population. PCR London Valves 2022, 28 November 2022, London, United Kingdom.
27.	Zhao ZG, Chen F, Wei X, et al. Transcatheter mitral valve implantation in severely calcified rheumatic mitral stenosis without annular calcification. Eur Heart J, 2022, 43(37): 3594.
28.	Januzzi JL, Omar AMS, Liu Y, et al. Association between sacubitril/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: The PROVE-HF Study. Circulation, 2022, 146(21): 1638-1640.

1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: A population-based study. Lancet, 2006, 368(9540): 1005-1011.
2. Goel K. COAPT PAS: 1 year outcomes from 5000 patients. ESC 2022, 28 August 2022, Barcelona, Spain.
3. Tang G. One-year outcomes in patients with secondary MR outside the COAPT criteria: From the MitraClip™ global EXPAND study. TVT 2022, 8 June 2022, Chicago, USA.
4. Jasona R. Contemporary clinical and echocardiographic outcomes of 1000+ patients treated with mitraClip™ G4: Results from the EXPAND G4 Post Approval Study. TCT 2022, 18 September 2022, Boston, USA.
5. Munafò AR. Two-year outcomes of MitraClip as a bridge to heart transplantation: The MitraBridge Registry. EuroPCR 2022, 17 May 2022, Paris, France.
6. Song C, Madhavan MV, Lindenfeld J, et al. Age-related outcomes after transcatheter mitral valve repair in patients with heart failure: Analysis from COAPT. JACC Cardiovasc Interv, 2022, 15(4): 397-407.
7. Beohar N, Ailawadi G, Kotinkaduwa LN, et al. Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: The COAPT trial. Eur Heart J, 2022, 43(17): 1639-1648.
8. Simard T, Vemulapalli S, Jung RG, et al. Transcatheter edge-to-edge mitral valve repair in patients with severe mitral regurgitation and cardiogenic shock. J Am Coll Cardiol, 2022, 80(22): 2072-2084.
9. Rubbio A. MitraClip in atrial functional mitral regurgitation: A multi-center experience The MITRA-TUNE Registry. EuroPCR 2022, 17 May 2022, Paris, France.
10. Doldi P, Stolz L, Orban M, et al. Transcatheter mitral valve repair in patients with atrial functional mitral regurgitation. JACC Cardiovasc Imaging, 2022, 15(11): 1843-1851.
11. Sodhi N, Asch FM, Ruf T, et al. Clinical outcomes with transcatheter edge-to-edge repair in atrial functional MR from the EXPAND study. JACC Cardiovasc Interv, 2022, 15(17): 1723-1730.
12. Tanaka T, Sugiura A, Öztürk C, et al. Transcatheter edge-to-edge repair for atrial secondary mitral regurgitation. JACC Cardiovasc Interv, 2022, 15(17): 1731-1740.
13. Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv, 2022, 15(24): 2523-2536.
14. Hausleiter J. The PASCAL ⅡD Registry: A prospective registry for transcatheter edge-to-edge repair in prohibitive risk patients with degenerative mitral regurgitation and complex mMitral valve anatomy. TCT 2022. September18, 2022, Boston, USA.
15. Lurz P. One-year outcomes for transcatheter mitral repair from the MiCLASP study. PCR London Valves 2022, 28 November 2022, London, United Kingdom.
16. Spargias K. Three-year outcomes for transcatheter mitral repair from the CLASP study. PCR London Valves 2022, 28 November 2022, London, United Kingdom.
17. Raposeiras-Roubin S, Adamo M, Freixa X, et al. A score to assess mortality after percutaneous mitral valve repair. J Am Coll Cardiol, 2022, 79(6): 562-573.
18. Latib A, Ho EC, Scotti A, et al. First-in-human transseptal transcatheter mitral chordal repair. JACC Cardiovasc Interv, 2022, 15(17): 1768-1769.
19. Scotti A, Galasso M, Margonato A, et al. Patient selection for trans-catheter mitral valve repair vs. replacement: Ongoing indications and glimpse to the future. Vessel Plus, 2021, 5: 6.
20. Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses. J Am Coll Cardiol, 2022, 80(23): 2171-2183.
21. Ben Ali W, Ludwig S, Duncan A, et al. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI Registry. Eur J Heart Fail, 2022, 24(5): 887-898.
22. Zahr F. Transfemoral TMVR: Intermediate-term outcomes from the Intrepid Early Feasibility Study. TCT 2022. September18, 2022, Boston, USA.
23. Jain REA. Midterm echocardiographic outcomes following transapical mitral valve replacement: Updates from the Intrepid Pilot Study. TCT 2022, September19, 2022, Boston, USA.
24. Rottbauer W. HighLife TSMVR and their latest experiences, moving forward. PCR London Valves 2022, 29 November 2022, London, United Kingdom.
25. Wild MG, Kreidel F, Hell MM, et al. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: A real-world multicentre experience. Eur J Heart Fail, 2022, 24(5): 899-907.
26. Duncan A. One-year outcomes of tendyne TMVR treating symptomatic MR: Expanded study population. PCR London Valves 2022, 28 November 2022, London, United Kingdom.
27. Zhao ZG, Chen F, Wei X, et al. Transcatheter mitral valve implantation in severely calcified rheumatic mitral stenosis without annular calcification. Eur Heart J, 2022, 43(37): 3594.
28. Januzzi JL, Omar AMS, Liu Y, et al. Association between sacubitril/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: The PROVE-HF Study. Circulation, 2022, 146(21): 1638-1640.

Previous Article
Interpretations of the NCCN guidelines for breast cancer risk reduction (version 2023)
Next Article
The 100 most cited studies on surgical treatment of myasthenia gravis: A bibliometric analysis

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Annual progress of transcatheter mitral valve intervention in 2022

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content